{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:16:27Z","timestamp":1768828587522,"version":"3.49.0"},"reference-count":28,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T00:00:00Z","timestamp":1654992000000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,5,8]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Persons with haemophilia A (PwHA) commonly experience regular bleeding into joints, which may result in joint damage and complications such as degenerative arthritis. Emicizumab has previously demonstrated efficacy in reducing the occurrence of joint bleeds and target joints, along with having a favourable safety profile; however, data on the long-term effects on joint health are lacking. The AOZORA study will evaluate the long-term safety and joint health of paediatric PwHA without factor (F)VIII inhibitors taking emicizumab; here, we report the details of the study protocol and baseline data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>AOZORA is a multicentre, open-label, phase IV clinical study in Japan that aims to enrol approximately 30 PwHA aged &lt;12 years without FVIII inhibitors. The primary endpoints include a long-term safety evaluation of adverse events, laboratory test abnormalities and FVIII inhibitor development; and a long-term joint health assessment using MRI and the Hemophilia Joint Health Score. Exploratory endpoints include characterising participants\u2019 physical activities and the number of activity-related bleeds requiring coagulation factor treatment. Currently, 30 participants have been enrolled, including 20 emicizumab-na\u00efve participants and 10 who transferred from HOHOEMI, a previous study in paediatric PwHA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The AOZORA study was approved by the Institutional Review Boards of Nara Medical University and the St Marianna University Group. The study will be conducted in compliance with the Declaration of Helsinki, the standards stipulated in paragraph 3 of Article 14 and Article 80-2 of the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act, the Ministerial Ordinance on Good Clinical Practice and the Ministerial Ordinance on Good Post-marketing Study Practice. Data will be published in peer-reviewed journals and presented at Global congresses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>JapicCTI-194701.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-059667","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T11:36:15Z","timestamp":1655120175000},"page":"e059667","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab \u2013 protocol for a multicentre, open-label, phase IV clinical study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-7061","authenticated-orcid":false,"given":"Midori","family":"Shima","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7707-4778","authenticated-orcid":false,"given":"Hideyuki","family":"Takedani","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, IMSUT Hospital, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0559-8366","authenticated-orcid":false,"given":"Kaoru","family":"Kitsukawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Taki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3896-5313","authenticated-orcid":false,"given":"Akira","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Division of Hematology, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-1498","authenticated-orcid":false,"given":"Azusa","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruko","family":"Yamaguchi-Suita","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Kyogoku","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seitaro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Clinical Development Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-2194","authenticated-orcid":false,"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"2025121510312046000_12.6.e059667.1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"2025121510312046000_12.6.e059667.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26 Suppl 6","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"2025121510312046000_12.6.e059667.3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.15256\/joc.2011.1.2","article-title":"Haemophilia and joint disease: pathophysiology, evaluation, and management","volume":"1","author":"Knobe","year":"2011","journal-title":"J Comorb"},{"key":"2025121510312046000_12.6.e059667.4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.650"},{"key":"2025121510312046000_12.6.e059667.5","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia a","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"key":"2025121510312046000_12.6.e059667.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04611.x"},{"key":"2025121510312046000_12.6.e059667.7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"Manco-Johnson","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025121510312046000_12.6.e059667.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-683169"},{"key":"2025121510312046000_12.6.e059667.9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121510312046000_12.6.e059667.10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"2025121510312046000_12.6.e059667.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"2025121510312046000_12.6.e059667.12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"2025121510312046000_12.6.e059667.13","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (Haven 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025121510312046000_12.6.e059667.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226"},{"key":"2025121510312046000_12.6.e059667.15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006684"},{"key":"2025121510312046000_12.6.e059667.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20353"},{"key":"2025121510312046000_12.6.e059667.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02883.x"},{"key":"2025121510312046000_12.6.e059667.18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2516.2008.01750.x","article-title":"Musculoskeletal measurement tools from the International prophylaxis Study Group (IPSG)","volume":"14 Suppl (3)","author":"Feldman","year":"2008","journal-title":"Haemophilia"},{"key":"2025121510312046000_12.6.e059667.19","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"2025121510312046000_12.6.e059667.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"2025121510312046000_12.6.e059667.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.01045.x"},{"key":"2025121510312046000_12.6.e059667.22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2019001238","article-title":"MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia","volume":"4","author":"Foppen","year":"2020","journal-title":"Blood Adv"},{"key":"2025121510312046000_12.6.e059667.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"2025121510312046000_12.6.e059667.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01953.x"},{"key":"2025121510312046000_12.6.e059667.25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/hae.13770","article-title":"Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia a children","volume":"25","author":"Chozie","year":"2019","journal-title":"Haemophilia"},{"key":"2025121510312046000_12.6.e059667.26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures","volume":"3","author":"Evans","year":"2010","journal-title":"J Exp Stroke Transl Med"},{"key":"2025121510312046000_12.6.e059667.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"2025121510312046000_12.6.e059667.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140768","article-title":"Factors Associated with Clinical Research Recruitment in a Pediatric Academic Medical Center--A Web-Based Survey","volume":"10","author":"Denhoff","year":"2015","journal-title":"PLoS One"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-059667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:31:29Z","timestamp":1765823489000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-059667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,13]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2021-059667"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-059667","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}